Abstract
Nicotinamide (NAM, a variant of vitamin B3) has recently been shown to accelerate the activation of human CD4+ and CD8+ T cells exposed to repeated CD3/CD28 agonism in vitro. Here, we demonstrate that T cells infiltrating mouse mammary carcinomas that are therapeutically controlled by NAM also express multiple markers of late-stage activation. Taken together, these findings lend additional support to the notion that the antineoplastic effects of NAM involve at least some degree of restored cancer immunosurveillance.
Original language | English |
---|---|
Article number | 251 |
Journal | Journal of Translational Medicine |
Volume | 20 |
Issue number | 1 |
DOIs | |
State | Published - May 3 2022 |
Externally published | Yes |
Keywords
- CTLA4
- Immune checkpoint inhibitors
- Immunotherapy
- LAG3
- PD-1
- TIM-3
- Niacinamide/pharmacology
- Tumor Microenvironment
- CD8-Positive T-Lymphocytes
- Animals
- Lymphocytes, Tumor-Infiltrating
- Programmed Cell Death 1 Receptor
- Mice